Hepatitis E and Pregnancy: An Unholy Alliance Unmasked from Kashmir, India

Mohammad Sultan Khuroo

Digestive Diseases Centre, Dr. Khuroo’s Medical Clinic, Srinagar, Jammu and Kashmir 190010, India; khuroo@yahoo.com; Tel.: +91-9906591044

Abstract: The adverse relationship between viral hepatitis and pregnancy in developing countries had been interpreted as a reflection of retrospectively biased hospital-based data collection by the West. However, the discovery of hepatitis E virus (HEV) as the etiological agent of an epidemic of non-A, non-B hepatitis in Kashmir, and the documenting of the increased incidence and severity of hepatitis E in pregnancy via a house-to-house survey, unmasked this unholy alliance. In the Hepeviridae family, HEV-genotype (gt)1 from genus Orthohepevirus A has a unique open reading frame (ORF)4-encoded protein which enhances viral polymerase activity and viral replication. The epidemics caused by HEV-gt1, but not any other Orthohepevirus A genotype, show an adverse relationship with pregnancy in humans. The pathogenesis of the association is complex and at present not well understood. Possibly multiple factors play a role in causing severe liver disease in the pregnant women including infection and damage to the maternal-fetal interface by HEV-gt1; vertical transmission of HEV to fetus causing severe fetal/neonatal hepatitis; and combined viral and hormone related immune dysfunction of diverse nature in the pregnant women, promoting viral replication. Management is multidisciplinary and needs a close watch for the development and management of acute liver failure. (ALF). Preliminary data suggest beneficial maternal outcomes by early termination of pregnancy in patients with lower grades of encephalopathy.

Keywords: hepatitis E; hepatitis E virus; genotypes; pregnancy; epidemic hepatitis; sporadic hepatitis; acute liver failure; fetus; neonate; delivery; hepatitis E vaccine

1. Historical Background

Space-time clustering of events in which people fall acutely ill with jaundice, quickly slip into a coma and die, is an alarming situation, more so when the victims are mostly or exclusively pregnant women [1].

The association between epidemics of jaundice and pregnancy has long been reported in scientific literature. The earliest recorded epidemic of jaundice with high mortality in pregnant women was reported from the French Caribbean colony Martinique in the year 1858 [2]. A strange disease had struck the island which left 24 women dead, and 20 of these were pregnant. All the deceased pregnant women had delivered stillborn babies. None of the jaundiced soldiers, all males, in the nearby garrison had died. Another notable epidemic of jaundice occurred in Paris in 1871. Deaths occurred exclusively in gestating women and autopsies revealed acute yellow atrophy of the liver as the cause of death [3].

Over the ensuing decades until 1946, many countries in Europe recorded several epidemics of jaundice with high death rates in pregnant women [1]. These epidemics also reported high rates of fetal and neonatal deaths as a result of abortions, premature deliveries, miscarriages, and stillbirths in both dead and surviving pregnant women. All these outbreaks were likely to have been related to hepatitis E; however, no serological tests of sera from such outbreaks are available. With improvement in economic conditions and clean water supplies, epidemic disease with high mortality in pregnant women is no longer reported from industrialized countries [4].
2. Controversy Over Data—West versus East

In the latter part of the last century, viral hepatitis and pregnancy was a matter of investigation and controversy [5]. The data published from various industrialized countries of Europe, North America and Australia had indicated that pregnancy does not increase the severity of disease and/or susceptibility to infection [6–10]. This was expected as hepatitis E was not endemic in such regions of the world [11]. However, several reports from developing countries in Asia especially India, Iran, and the Middle East, had shown that there is increased severity and mortality from viral hepatitis among pregnant women [12–16]. These reports were based on retrospective analysis of hospital admissions and were interpreted in some studies as a reflection of biased hospital-based data collection, due to the fact that these data predated the discovery of HEV [17].

3. Unmasking the Unholy Alliance

The association between viral hepatitis and pregnancy was delineated with the discovery of HEV from an epidemic of viral hepatitis in Kashmir, India [18] and the reporting of the true incidence and severity of the disease in pregnancy based via a prospective door-to-door study [19] (Figure 1).

Figure 1. Gulmarg Kashmir Epidemic, 1978–1979. (A) Upper panel. The epidemic curve with the weekly occurrence of hepatitis E cases. The region had an open-source water supply from a canal (Ningli Nallah) which originates from the Alpather Lake situated at the foot of Apharwat Peaks, Gulmarg. After passing through mountains as the world-famous Sharanz waterfall, the stream crosses the valley to join the Wular lake. The canal along its route is used for multiple purposes including drinking water, linen washing, swimming, fishing, and sewage and garbage disposal, and thus stays highly polluted. Lower panel. The data on incidence and severity of viral hepatitis in men (15–45 years), NPF (nonpregnant females; 15–45 years) and PF (pregnant females) were collected by four door-to-door surveys done at 4 to 6 week intervals during the epidemic. (B) Kashmir strain of HEV (Pinglina epidemic, 1993–94, Kashmir, India [20]). Unrooted phylogenetic tree generated by Maximum Likelihood method using MEGA software (version 10.1.8), on the basis of 326 bp sequences of HEV ORF1 genomic. Reference sequences of different HEV genotypes from GenBank are shown in gray filled circles. Kashmir strain of HEV was of genotype 1 with country specific HEV sequences are shown in color filled circles. Kashmir strain of HEV was of genotype 1 with 94.6% homology with the Burmese isolates of HEV (Courtesy Saleem Kamili & Xia, Guo-Liang, both at CDC, Atlanta, Georgia). α = 6 pregnant women died.
3.1. Discovery of Hepatitis E

The discovery of HEV started with studies carried out on a large-scale epidemic of viral hepatitis in Gulmarg-Kashmir, India in November 1978 [18]. Investigating an epidemic of the size had posed problems of harsh weather, primitive healthcare facilities, a highly compressed time period, lack of funding, and hesitancy of medical manpower to join the team due to fear of personal health risks. To face the challenges, a team of 500 healthcare workers (local inhabitants) opted to reside in the epidemic region, support the primitive healthcare facilities, offer care to the needy at the doorstep, and record every case of hepatitis from the community (Figure 1). Over 9 weeks, 20,083 cases of acute viral hepatitis (AVH) with 600 fatalities were recorded. The epidemic curve was highly compressed with the occurrence of up to 4000 icteric cases per week. The disease selectively affected young adults and presented as acute hepatitis syndrome with cholestatic features in around 20% of the affected individuals. Liver histology showed portal and lobular hepatitis with necrosis and ballooning degeneration and Kupffer cell hyperplasia, with a subset of patients showing distinctive features in the form of intracanalicular bile stasis and rosette formation of hepatocytes as a dominant feature. All patients who survived recovered and none developed chronic liver disease [21]. IgG anti-HAV, as a marker of past exposure and immunity to hepatitis A virus (HAV), was reactive in all patients, while none was seropositive for IgM anti-HAV, HBsAg, and IgM anti-HBc. It was postulated that this epidemic of enterically transmitted non-A, non-B hepatitis (ET-NANBH), was caused by an agent different from post-transfusion non-A, non-B hepatitis (PT-NANBH), later identified as hepatitis C virus (HCV) [22].

Mikhail Balayan self-infected himself via stool samples from an outbreak of hepatitis that occurred among Soviet troops in Afghanistan. He and his team identified virus-like-particles (VLPs) in his stool samples [23]. Reyes et al. isolated a cDNA from the virus responsible for ET-NANBH in a stool from Burma [24]. Tam et al. cloned and sequenced the full length of HEV [25] and Yarbough et al. developed a serological test for diagnosis of HEV infection [26].

After these developments, sera samples (n = 114) collected during the Gulmarg Kashmir epidemic 1978–79, 71% tested positive for IgG anti-HEV and 75% of these were reactive for IgM anti-HEV, confirming HEV as the causative agent of the epidemic [27]. From 1978 to 2013, ten epidemics of viral hepatitis were reported from Kashmir, India [18,19,28–30]. Sera from all ten epidemics were tested for IgG anti-HEV, IgM anti-HEV and HEV RNA and the epidemics were confirmed to be caused by HEV [20,30–32]. Partial genomic sequencing of HEV from two such epidemics, namely the Jammu epidemic 1988 and the Pinglina epidemic of 1993–94, were carried out. Both virus strains belonged to HEV-gt1 and had a homology of 94.6%–96.8% to the Burmese strain of HEV (Figure 1) [20,33].

3.2. Incidence and Severity of Hepatitis E in Pregnancy

During the Gulmarg-Kashmir epidemic of 1978–79, a prospective study was done to define the incidence and severity of hepatitis E in pregnant women compared with non-pregnant women of child-bearing age and men (15–45 years) [19]. The data were collected in Block Sopore, consisting of 15 villages with a population of 16,620. The four door-to-door surveys were conducted at 4-to-6-week intervals to identify every new case of hepatitis (Figure 1). A total of 275 cases of hepatitis E were recorded. Thirty-six (17.3%) of the 208 pregnant women were infected with HEV as compared to 71 (2.1%) of 3350 nonpregnant women and 107 (2.8%) of 3350 men. The incidence of disease in the first trimester (3/34; 8.8%), second trimester (15/77; 19.2%), and third trimester (18/97; 18.6%) was higher when compared to that in nonpregnant women and men. Acute liver failure (ALF) developed in 22.2% (8/36) of pregnant women with HEV infection, as compared to 2.8% (3/107) of men and no (0/71) nonpregnant women. Nine deaths had occurred, six in pregnant women and three in men. The case fatality rate of HEV infection was 16.6% (6/36) in pregnant women and 2.8% (3/107) in men. None of the nonpregnant women with HEV infection died. None of the 18 pregnant women with HEV infection in their first and second
trimester developed ALF, while 8 (44.4%) of 18 pregnant women with HEV infection in
the third trimester developed acute hepatic failure with six deaths. The case fatality rate
of HEV infection in the third trimester of pregnancy was 33.3% (6/18). These data were
conclusive that, during epidemics, HEV infection showed increased incidence and severity
in pregnancy. The incidence was higher in all three trimesters as compared to HEV-infected
men and non-pregnant women, while the increased severity of disease was restricted to
the third trimester of pregnancy.

4. Hepatitis E

Hepatitis E is one of the five main forms of viral hepatitis and is caused by infection
with HEV [34]. HEV is a group of viruses in the family Hepeviridae [35]. These viruses are
quasi-enveloped, have an icosahedral shape with 20 faces, spherical geometry with surface
spikes and indentations, and T = 1 symmetry. Genomes are linear, non-segmented, 7.2 kb in
length, and have three open reading frames (ORFs), namely ORF1, ORF2 and ORF3 [36].
HEV has marked genetic heterogeneity and is divided into two genera, namely Orthohepe-
ivirus and Piscihepevirus [37]. Orthohepevirus has four species A, B, C and D. Orthohepevirus A
has eight genotypes (gt). HEV-gt1 and HEV-gt2 infect humans alone. An additional ORF4,
spanning nt2835-3308 and overlapping with ORF1, is present in HEV-gt1 alone and its
protein expression is regulated via an IRES-like RNA element (nt2701-2787). ORF4 appears
to cause endoplasmic reticulum (ER) stress which may be involved in promoting viral
replication [38,39] (Figure 2). As C-terminal 19 amino acids are absent in around half of the
genomes, only the N-terminal 124 amino acids of pORF4 can interact with other viral and
host proteins. This protein functions to enhance viral polymerase activity and promote
viral replication and is indispensable for the HEV-gt1 life cycle [40]. HEV-gt3 and HEV-gt4
are highly divergent and have been isolated from several animals including pig, wild boar,
deer, mongoose, rabbit, goat, horse, bottlenose dolphin, and sheep (HEV-gt3); and pig,
wild boar, cattle, cow, sheep, goat, and yak (HEV-gt4) [41,42]. HEV-gt5 and HEV-gt6 infect
wild boar in Japan and HEV-gt7 and HEV-gt8 infect dromedary and Bactrian camels, respec-
tively [43]. HEV-gt3 and HEV-gt4 from pigs and possibly rabbits are zoonotic, and isolated
cases of HEV-gt7 infection in humans have been reported [36,37]. Orthohepevirus B has four
 genotypes, infects birds, primarily chicken, and causes hepatitis-splenomegaly syndrome
and big liver-spleen disease in chicken. Orthohepevirus C causes infection in rats, voles, mice,
and ferret and Orthohepevirus D infects bats. Cases of rat HEV infection in humans have
been reported [44,45]. Genus Piscihepevirus includes a single species containing cutthroat
trout virus [37]. Isolates from moose, fox, and little egret have remained unassigned as
yet [35,37]. A recent study showed that people in households with seropositive goats were
more likely to be seropositive themselves than persons living in households with seronega-
tive goats [46]. Hepatitis E is a global disease and was estimated to have caused 20.1 million
incident infections in the year 2005, out of which approximately 3.4 million infections were
symptomatic with around 70,000 deaths and 3000 stillbirths [47]. Hepatitis E has distinctive
epidemiological and clinical characteristics in developing countries, which contrast sharply
with those in the industrialized world [48,49]. Based on disease pattern and prevalence
and genotype distribution, four hepatitis E epidemiological patterns are seen [11]. The first
is an hyperendemic zone that encompasses many countries in the Indian subcontinent,
Southeast Asia, Central Asia, many regions in Africa, and Mexico. Here HEV-gt1 and
HEV-gt2 present as an epidemic and an endemic disease. The second is an endemic zone
that involves several countries in the Middle East and South America and some regions
of Southeast Asia (Singapore). HEV-gt1 causes one-fourth of sporadic hepatitis and ALF
in these countries. Epidemics of hepatitis E do not occur. The third epidemiological zone
is limited to Egypt wherein HEV-gt1 infections occur at young age similar to hepatitis A.
Recent studies have shown that symptomatic HEV infections do occur in elderly people
and those with pre-existing liver diseases. [50–52]. Seroprevalence studies have shown
high occurrence of asymptomatic infections in the general population as well as pregnant
women [53,54]. This could be related to zoonotic food-borne exposure to HEV-gt3 through
cow’s milk, goat milk and goat liver [46,55,56]. It was also observed that naturally acquired immunity appear to protect HEV-exposed subjects from contracting HEV infection during an epidemic [57]. HEV-gt3 and HEV-gt4 cause sporadic autochthonous zoonotic food-borne infection in industrialized countries, which constitute the fourth zone. HEV-gt3 has been reported from many European countries, North and South America, Russia, Japan, and Australia; while HEV-gt4 is prevalent in many regions of China, several Southeast Asian countries, Japan, and a few countries in Europe.

Figure 2. Hepatitis E virus Genotype 1. Genomic organization. (a) The hepatitis E virus genome; (b) Genomic RNA and bicistronic sub-genomic RNA; (c) Four Open reading frames (ORFs) and (d) Four encoded proteins (pORF1, pORF2, pORF3, and pORF4). ORF4, spanning nt2835-3308 and overlapping ORF1 in present in HEV genotype 1 alone, and its protein expression is regulated via an IRES-like RNA element (nt2701-2787). ORF4 encodes a protein (pORF4) of 124 aa, which functions to enhance viral polymerase activity and promote viral replication and is indispensable for the HEV genotype 1 life cycle.

5. Epidemic Hepatitis E and Pregnancy

Several large-scale water-borne epidemics of hepatitis have been reported from many regions of the developing world [1] (Table 1). Initially, these epidemics were designated empirically as ET-NANBH based on serological testing for HAV and HBV infections. Later, once serological testing for HEV infection was available, most such epidemics were found to be caused by HEV. HEV strains, once characterized, were all of HEV-gt1 [58,59]. Epidemic HEV infections had several features in common including occurrence in young adults (15–45 years), significant cholestatic features, self-limiting disease, and high mortality in pregnancy.

Table 1. Epidemics of hepatitis E with number of recorded cases, case fatality rate (overall and in pregnant women) and relationship with hepatitis E virus genotypes.

| Region Year [References µ] | Number of HEV Infections | CFR (%) | HEV Genotypes |
|----------------------------|--------------------------|---------|---------------|
|                            | Overall | Pregnancy |              |
| Kashmir 1978–2013 [18–20,28–30,32,33] | 55,563 | 3.19 | 22.0 | HEV-gt-1 |
| New Delhi 1956 [58,60,61] | 29,300 | 0.9 | 10.5 | HEV |
| Kanpur 1991 [62] | 79,091 | 0.06 | 27.0 | HEV |
From 1978 to 2013, 10 large-scale water-borne epidemics of hepatitis E were recorded in Kashmir [18–20,28–30,32,33]. A total of 55,563 persons had contracted the disease and 1775 died with a case fatality rate (CFR) of 3.19%. CFR of HEV in pregnant women during these epidemics was 22%. A retrospective analysis of sera from a large-scale water-borne epidemic that occurred in Delhi in 1955–56 revealed that the epidemic was caused by HEV [58,60,61]. This epidemic affected an estimated 29,300 patients with 266 deaths. Overall, CFR was 0.9% and CFR in pregnancy was 8.5%. A massive epidemic of hepatitis E involving an estimated 79,000 cases visited Kanpur, UP, India in 1992, with a CFR of 27% in pregnant women [62]. Several other outbreaks have been reported from other parts of India [63,64,104–106], Pakistan [66–68,107], Burma [25,69], Nepal [70–72], and Bangladesh [73–75,108,109], and all of these showed high CFR in pregnant women [58]. Several regions in Central Asia namely Turkmenistan [76,77], Uzbekistan [78,79], Tajikistan [110], and Kirgizstan [111], have been hit by epidemics of viral hepatitis caused by HEV-gt1. These epidemics affected between 10,000 and 30,000 persons and saw high mortality in pregnant women with CFR ranging from 7% to 27%. Xinjiang region in the northwest of China recorded a massive outbreak of viral hepatitis affecting 120,000 people (mostly Uighurs) in the autumn of 1987–88. CFR in pregnant women was 13% [80]. The outbreak was later confirmed to be caused by HEV-gt1 [81]. Regions of South-East Asia, namely Indonesia [82] and Vietnam, [112] have reported several epidemics of hepatitis E with a high fatality rate of up to 26% in pregnant women. Several outbreaks caused by HEV-gt1 have been reported from many regions of Africa including Somalia [87,90], Al-

### Table 1. Cont.

| Region              | Year       | Number of HEV Infections | CFR (%) | HEV Genotypes     |
|---------------------|------------|--------------------------|---------|-------------------|
| Azamgarh            | 1982 [63]  | 152                      | 12      | 39.0              |
| Kolhapur            | 1981 [58,64,65] | 1169                  | 0.25    | 8.33              |
| Islamabad           | 1997 [66–68]| 3827                    | 0.2     | 11.4              |
| Rangoon             | 1985 [25,69]| 399                     | 3.5     | 12.0              |
| Kathmandu           | 1981 [70,71]| 12,000                  | -       | 21.0              |
| Kathmandu           | 1987 [71,72]| 7405                    | 0.41    | 24.65             |
| Bangladesh          | 2008 [73,74]| 4198                    | 0.47    | 19.0              |
| Bangladesh          | 2010 [74,75]| 2162                    | 0.55    | 25                |
| Turkmenistan        | 1985 [76,77]| 16,175                  | 0.12    | 27.4              |
| Uzbekistan          | 1985 [78,79]| 12,000                  | -       | 7.1               |
| Xinjiang            | 1986 [80,81]| 120,000                 | 0.59    | 13.3              |
| Indonesia           | 1991 [82]  | 1688                     | 1.78    | 26.3              |
| Algeria             | 1980 [83,84]| 788                     | 1.39    | 100               |
| Sudan               | 2006 [85,86]| 253                     | 13.5    | 31.1              |
| Djibouti            | 1998 [87,88]| 42                      | 9.5     | 33.3              |
| Central African Republic | 2002 [87,89] | 715                    | 0.55    | 14.28             |
| Somalia             | 1993 [87,90]| 11,413                  | 2.9     | 13.8              |
| Kenya               | 1991 [91,92]| 1702                    | 3.70    | 14.28             |
| Sudan               | 2004 [85,87]| 2621                    | 1.71    | 31.14             |
| Uganda              | 2007 [93]  | 4789                     | 1.50    | 6.87              |
| Mexico              | 1986 [94]  | 223                      | 1.35    | 0                 |
| Namibia             | 1995 [95]  | >600                     | 0.50    | 1 deathβ         |
| Namibia             | 1983 [96,97]| 201                     | 3.48    | 85.7              |
| Nigeria             | 2018 [98,99]| 146                     | 1.37    | 8                 |
| Central African Republic | 2008 [100] | 222                    | 1.8     | 20                |
| Chad                | 2004 [101] | 989                     | 3.0     | -                 |
| Namibia             | 2017 [102] | 7247                    | 0.80    | 6.00              |
| Chad                | 2016 [103] | 1293                    | 0.69    | 3.16              |

CFR = Case fatality rate, gt = genotype, ENANBH = Epidemic non-A, non-B hepatitis, β = number of pregnant women not mentioned in calculating CFR. µ = The references include reports of the epidemic and further studies on the stored samples to characterize the epidemic and the HEV genotypes.
Viruses 2021, 13, 1329

geria [83,84,113], Côte d’Ivoire [114], Botswana [115], Djibouti [87,88] and Central African Republic [87,89], with higher fatality in pregnant women. Of late, outbreaks of hepatitis E in refugee camps among displaced people in several African countries including Somalia [87,90,116], Kenya [91,92], Sudan [85,86] and Uganda [93,117] have occurred. All these epidemics have reported higher death rates in pregnant women.

HEV-gt2 was the incriminating agent for two outbreaks of hepatitis that occurred in two villages 70 km south of Mexico City in 1986 [94]. Of the 223 cases, three women died with an overall CFR of 1.35%. Higher fatality in pregnant women was not reported. The epidemic caused by HEV-gt2 from Namibia in 1995 also did not report higher deaths in pregnant women [92,95,102]. However, a previously reported epidemic from Namibia in 1983 was caused by HEV-gt1 [96,97] and of the 201 cases six of the seven deaths were seen in pregnant women. Epidemics of hepatitis in Nigeria [98,99], Central African Republic [100], and Chad [101,103] were caused by both HEV-gt1 and HEV-gt2 and all reported higher deaths in pregnant women. Few cases of HEV-gt3 and HEV-gt4 infections reported in pregnant women have not been associated with severe disease or deaths [118,119]. An HEV-gt3 outbreak on a cruise ship causing 33 infections did not cause higher mortality in pregnant women [120]. HEV-gt3 and HEV-gt4 are prevalent in industrialized countries and have not been associated with higher mortality in pregnant women [121]. Thus, higher mortality of epidemic hepatitis E in pregnancy is genotype-specific and associated with HEV-gt1 and not with other genotypes causing human infections, namely HEV-gt2, HEV-gt3, and HEV-gt4. However, adverse pregnancy outcomes including miscarriage and stillbirths have been reported in pregnant rabbits experimentally infected with HEV-gt3 and HEV-gt4 [122–124].

6. Sporadic Hepatitis E and Pregnancy

In 1983, 293 patients with acute sporadic viral hepatitis, of whom 155 cases were caused by HEV infections were reported [20,125]. The mode of transmission was enteric, mostly based on person-to-person contact. The disease occurred in young adults with relative sparing of children. The clinical profile resembled AVH with cholestasis in a subset of patients. The disease was self-limiting and none of the patients developed chronic hepatitis or cirrhosis on follow-up. All these features resembled the epidemic HEV described from Kashmir [18]. The disease occurred in 19 pregnant women. The overall case fatality rate (CFR) was 12.3% and CFR in pregnant women was 35.6%. After this, the etiology, clinical course, and outcome of AVH in 76 pregnant women and 337 non-pregnant women of childbearing age were studied [126]. The prevalence of HEV in pregnant women was 85.5% (65/76 patients) as against 41.5% (140/337) in nonpregnant women. The prevalence of HEV infection was 76.9% (4/13), 88.9% (12/18), 83.8% (23/37), and 100% (8/8) in first, second, third trimesters, and puerperium, respectively. The CFR of HEV infection in pregnant women was 69.2% (45/65) as against 10.0% (14/140) in nonpregnant women. The CFR was 40% (4/10) in the first trimester as against 74.5% (41/55) in the second trimester and beyond. A north Indian study reported HEV as the cause of acute sporadic hepatitis in 82%, 49%, and 57% of pregnant women, nonpregnant women, and men, respectively [127]. Several other studies of acute sporadic viral hepatitis showed a higher prevalence of HEV infections and higher CFR in pregnant women [128–132] (Table 2).

Regarding HEV genotypes prevalent in acute sporadic hepatitis in India, Arankalle et al. [65] studied 17 HEV isolates (both epidemic and sporadic) from India and found all to be related to various subtypes of HEV-gt1. In another study, Indian swine were found to be infected by HEV-gt4, while all Indian human isolates studied were HEV-gt1 [133]. Gupta et al. [59] studied sequences of 74 patients with acute sporadic hepatitis E from North India and found all the isolates were related to HEV-gt1a. Thus, HEV circulating in India and causing acute sporadic viral hepatitis with higher mortality in pregnancy is also genotype-specific and associated with HEV-gt1.
Table 2. Prevalence of HEV infection among pregnant women with acute sporadic viral hepatitis.

| Author, Year, [References] | Study Material | HEV-AVH (%) | HEV-ALF (%) | HEV Status |
|----------------------------|----------------|-------------|-------------|------------|
|                            | PF Others      | PF Others   | PF Others   |            |
| Khuroo et al., 1983 [125]  | 27 266α        | 19 (70.4)   | 136 (51.1)  | HEV        |
| Nayak et al., 1989 [127]   | 169 70β        | 138 (81.6)  | 34 (48.6)   | ETNANBH    |
| Jaiswal et al., 2001 [129] | 127 146β       | 83 (65.4)   | 129 (88.4)  | HEV        |
| Khuroo et al., 2003 [126]  | 76 337β        | 65 (85.5)   | 140 (41.5)  | HEV        |
| Beniwal et al., 2003 [130] | 97             | 46 (47.4)   | -           | HEV        |
| Patra et al., 2007 [128]   | 220            | -           | 73 (35.3)   | HEV        |

PF = Pregnant females, α = all age groups, β = nonpregnant women of childbearing age.

7. HEV-ALF and Pregnancy

Several large series of ALF and its relationship with pregnancy have been reported from India. In one study, amongst 180 patients with ALF [134] forty-nine of the 111 women were pregnant. Seventy-nine patients were related to HEV and the remaining 101 patients were caused by HAV (4 cases), HBV (25 cases), HCV (13 cases), HDV (two cases), drug (one case), and non-A-E agents (56 cases). HEV was the cause of ALF in 47 of the 49 pregnant women as against 14 of the 34 nonpregnant women of childbearing age. Acharya et al. [135] from the All India Institute of Medical Sciences (AIIMS), New Delhi, reported 423 patients with ALF. Of the 223 women, 53 were pregnant. The etiology included HAV (seven cases), HBV (117 cases), HDV (16 cases), NANBH (264 cases), and drugs (19 cases). Thirty-one of the 50 cases from the NANBH group were caused by HEV. Subsequently, 1015 patients with ALF were reported from the same center. 249 of the 647 women were pregnant. HEV was the etiological cause in 342 patients, while 651 patients had non-HEV etiology [136]. HEV was the cause of ALF in 145 of the 244 pregnant women, 100 of the 329 nonpregnant women, and 97 of the 420 men. In addition, the occurrence of “Disseminated intravascular coagulation (DIC)” is a distinctive feature of HEV-ALF during pregnancy [140], resembling a Schwartzmann phenomenon.

The prognosis of HEV-ALF in pregnant women has been studied by several investigators [134,136]. The investigators from AIIMS, New Delhi, questioned the worse prognosis of HEV-ALF during pregnancy [136,141]. The authors compared the mortality rates in 249 pregnant women, 341 non-pregnant women, and 425 men, 15 to 45 years of age. The mortality rates in the three groups were 53.8%, 57.2%, and 57.9%, respectively (p = 0.572). A prospective study on 180 pregnant women with ALF revealed 79 with HEV-ALF and 101 with non-HEV-ALF [134]. The prognosis in patients with HEV-ALF was better than those with non-HEV-ALF (CFR 51.9% in HEV-ALF versus 84.2% in non-HEV-ALF). Factors predictive of poor prognosis included non-HEV etiology, prothrombin time > 30 s, grade of coma > 2, and age > 40 years and did not include pregnancy per se or duration of pregnancy. The fact that pregnant women acquired ALF more often did not mean that such patients will have higher mortality [142].
8. Proposed Hypothesis on Pathogenesis of Mortality in HEV-Infected Pregnant Women

The pathogenesis of higher morbidity and mortality due to HEV infection in pregnancy is complex and remains to be fully understood. The lack of a proper animal model to study the pathogenesis of HEV-gt1 in pregnancy has been an issue. Rhesus monkey (Macaca mulata) is an established animal model for HEV infection [32,143], but HEV-gt1 infection to pregnant monkeys does not result in ALF [144,145] and thus is not useful to study the pathogenesis of the disease. Pregnant rhesus monkeys can be infected with HEV-gt4 with resultant high viral titers, longer duration of infection, obstetric events and vertically transmitted fetal infections [146]. A successful animal model for HEV-gt4 has been established in pregnant BABL/c mice [147]. Rabbits are new animal models for hepatitis E, but HEV-gt1 is not infectious to the animal [148]. Besides occurrence of ALF in pregnant women, extrahepatic manifestations including neurological, renal, hematological, and pancreatic are associated with HEV infections. The pathogenesis of HEV in the extrahepatic tissues is either due to direct cytopathic effect mediated by the virus replication or immunological mechanisms caused by an uncontrollable host response [149]. Several important facts have recently emerged to explain the complex relationship between HEV and pregnancy (Figure 3).

Figure 3. Pathogenesis of hepatitis E virus-related acute liver failure in pregnancy. IAVH = icteric acute viral hepatitis, AIAVH = Anicteric acute viral hepatitis, HEV-ALF = Hepatitis E virus related acute liver failure.

8.1. HEV Genome, Heterogeneity and Variants in Pregnancy

The data available from epidemic and sporadic hepatitis E indicate that pregnant women acquire HEV [19,126] and develop ALF more often than others [134–136] and this phenomenon is limited to infection with HEV-gt1 [39,65]. Other hepatitis viruses (HAV, HBV and HCV) and other HEV genotypes (HEV-gt2 and HEV-gt3) do not cause higher deaths in pregnant women [150]. Among the HEV family, HEV-gt1 alone has ORF4 which encodes a protein, pORF4 of 124 aa [38,39]. The encoded pORF4 by the HEV-gt1 genome interact with other viral and host proteins, enhance viral polymerase activity and promote viral replication [123]. HEV-gt1, and not HEV-gt3, causes necrosis and apoptosis in the maternal–fetal interface possibly caused by mitochondrial damage and activation of caspase family membranes [151]. This leads to alterations of the placental barrier architecture and promotes vertical transmission [38]. High levels of HEV RNA related to HEV-gt1 have been correlated with increased severity of disease in pregnant
women [138,152]. HEV sequences in patients with HEV-ALF (five patients) were compared with those of HEV-AVH (five patients) and showed six unique amino acid substitutions in the ORF1 region of HEV [153], namely F179S, A317T, T735I, L1110F, V1120I, and F1439Y. Two of these (L1110F and V1120I) which occurred in the helicase domain pointing to its role in determining the outcome of HEV infections.

8.2. Immune Response in HEV Infected Pregnant Women

The immunological alterations in pregnancy are complex, showing immune tolerance to an allogenic fetus and host defense against pathogen. This is accomplished by the maternal–fetal interface (decidua) consisting of decidual stromal cells, decidual immune cells, and trophoblast cells [154]. The maternal–fetal interface contains natural killer (NK) cells, macrophages, dendritic, and T cells which interact with invading fetal extra-villous trophoblast for placentation, fetal growth, and pregnancy outcome [155]. Pregnancy suppresses cell-mediated immunity at the maternal–fetal interface to tolerate fetal antigens and maintains a normal humoral immune response against pathogens [156]. Pregnancy causes a shift from a Th1 to a Th2 cytokine response, allowing maternal–fetal tolerance for fetus development [157].

HEV-gt1 infection in pregnant women causes several alterations in innate and adaptive immune response, which helps virus replication and increases the severity of disease in the pregnant women [123]. Pregnant women with HEV-ALF have impaired macrophage phagocytic activity and downregulation of TLR3 and TLR9 expression, impeding MyD88-mediated IFN production [158]. This may lead to inadequate triggers for the innate immune response which in turn could lead to enhanced viral replication and severe liver injury. HEV-gt1 (but not HEV-gt3) in pregnant women was shown to evade early antiviral response and cause adverse consequences due to poor IFN response in placental cells [151]. Pregnant women with HEV-ALF have significantly higher levels of pro-inflammatory cytokines (TNF-alpha, IL-6, IFN-gamma, and TGF-beta) and this had a significant positive correlation with viral load, serum bilirubin, and prothrombin time. Increased severity of disease in pregnant women with HEV-ALF may be mediated through cytokines [159,160]. Pregnant women with HEV-ALF have lower CD4+ T cell counts, higher CD8+ T cell counts, and lowered CD4/CD8 ratio than women with HEV-negative ALF [161]. Pregnant women with HEV-ALF have excessive Th2 switching, which dysregulates balance between tolerance and immunity [162,163]. Pregnant women with HEV-ALF show higher DNA-binding activity of NF-κB and absence of p65 expression, leading to deregulated immunity and severe liver damage [164]. Recently the role of immune cells in the spread of HEV infection to various body organs has been studied. Immune cells are permissive to HEV and help the virus enter various body organs, as shown in vivo and in vitro studies [165,166]. It is possible that this may be one of the ways in which the virus reaches the maternal–fetal interface and causes vertical transmission.

8.3. Hormones and HEV in Pregnancy

Hormones in pregnancy may enhance HEV viral replication. Women experience a sudden and marked increase in estrogen and progesterone levels during pregnancy [167]. Estrogen helps the fetus to develop and mature. Progesterone suppresses the maternal immune response by stimulation of Th2 and reduction of Th1 cytokines, thereby preventing maternal rejection of the trophoblast [168]. Pregnant women with HEV infection have higher levels of estrogen, progesterone, and HCG than those without HEV infection. Higher hormone levels are apt to further dampen the immune response and help viral replication [155]. Estradiol has been shown to facilitate HEV replication in an in vitro experiment in A546 cells [169]. High estrogen in pregnancy causes placental dysfunction and leads to preterm delivery, low birth weight infants and fetal mortality [170]. Bose et al. [171] studied deregulation of the progesterone receptor signaling pathway in pregnant women with HEV-ALF, HEV infection, and healthy controls. Patients with HEV-ALF show proges-
terone receptor gene mutations and a high IL-12/IL-10 ratio and are associated with a poor maternal outcome.

### 8.4. Nutritional Status and HEV in Pregnancy

Malnutrition had been proposed to explain the reports of higher deaths with viral hepatitis in pregnancy in developing countries. However, the nutritional assessment of pregnant women in these reports had not been evaluated [13]. During the Gulmarg-Kashmir HEV epidemic 1978-79, caloric and protein intake as well as estimation of serum protein as an index of nutritional status in pregnant women were determined and compared with those in nonpregnant women (15–45 years) [19]. The caloric and protein intake and serum protein in pregnant women were within normal ranges (3242 ± 551 cal/day, 60 ± 20 g/day, and 3.3 ± 0.4 g/dL respectively) and did not differ from those seen in nonpregnant women (300 ± 450 cal/day, 50 ± 15 g/day, and 3.2 ± 0.6 g/dL; p > 0.50). The caloric and protein intake and serum proteins were well in acceptance with those recommended for Indian women [172]. Of significance was the observation that pregnant women who developed HEV-ALF had excellent nutritional status. Thus, malnutrition contributing to severe disease in pregnant women in developing countries was not collaborated by these data.

### 8.5. Fetal HEV Infections and Maternal Mortality, Obstetric Events and Neonatal Outcome

Morbidity and mortality among pregnant women and their neonates and obstetric events may be a reflection of the severity of the HEV infection in the mother [19,126,128]. However, there is growing evidence that vertically transmitted HEV infections causing fetal HEV infections may directly contribute to maternal mortality, obstetric events, and neonatal outcome [173]. Several investigators from India and the Middle East [140,174–183] have reported vertical transmission of HEV and resultant peri-natal morbidity and mortality (Table 3).

| Author Year, [References] | HEV-PF | Maternal & Obstetric Events | HEV-Neonatal Status | HEV-Infected Neonates | Pattern of Neonatal HEV Disease | Outcome of HEV-Infected Neonates |
|--------------------------|--------|-----------------------------|---------------------|----------------------|-------------------------------|---------------------------------|
| Khuroo et al., 1995 [174] | 10     | ALF 6, Died 3, (DUD 2), FTD 7, PD 1 | 8 | 6 (RNA 5, IgM 3, IgG-Seroconversion 1) | HEV-ALF 2, I-HEV 1, AI-HEV 3 | Died 2 (HEV-ALF, Liver biopsy 1 MHN), Recovered 4, RNA in 2 lasted 1 month. |
| Khuroo et al., 2009 [175] | 26     | ALF 15, Died 9 (DUD 5), FTD 15, PD 4, Ab 2 | 19 (Died 1 due prematurity) + 2 aborted. | 15 (RNA 10, IgM 12) | HEV-ALF 6, I-HEV 4, AI-HEV 5 | Died 6 (HEV-ALF, Liver biopsy 1 MHN with HEV RNA in liver), Recovered 9. RNA lasted for 4 weeks in 4, 8 weeks in 1, 32 weeks in 1. IgM lasted for 4 weeks in 3, for 8 weeks in 2. |
| Khuroo et al., 2006 [140] | 36     | ALF 16, DIC 9, Died 10, FTD 26, PD 7, Ab 3 | 33 + 3 aborted. | 25 (RNA 20, IgM 24) | HEV-ALF 14, I-HEV 9, AI-HEV 2 | Died 14 (HEV-ALF, Liver biopsy 14 MHN), Recovered 11. |
| Kumar et al., 2001 [177] | 28     | ALF 6, Died 3 (DUD 2), PD 2 | 26 | 26 (RNA 26) | HEV-ALF 2, I-HEV 21, AI-HEV 3 | Died 2 (HEV-ALF), Recovered 24. |
| Singh et al., 2003 [176] | 22     | ALF 14, Died 14. | NK *, 6 | 3 (RNA 3) | - | - |
| Kumar et al., 2004 [178] | 28     | ALF 9, Died 7, PD 18. | NK *, 18 | 6 (RNA 4, IgM 3) | - | - |
| Chibber et al., 2004 [179] | 92     | FTD 92 (Vaginal delivery 80, Caesarean in 12) | 92 | 4 (RNA 4, IgM 4) | I-HEV 4 *** | - |
| El Sayed Zaki et al., 2013 [181] | 9      | 9 ** | 9 | 9 (RNA 5, IgM 1, IgG 6) | RDS with icterus 5, I-HEV 3, Sepsis 1. | - |
Table 3. Cont.

| Author Year, [References] | HEV-PF | Maternal & Obstetric Events | HEV-Neonatal Status | HEV-Infections | Pattern of Neonatal HEV Disease | Outcome of HEV-Infected Neonates |
|---------------------------|--------|----------------------------|---------------------|---------------|-------------------------------|---------------------------------|
| Sharma et al., 2017 [180] | 144    | ALF 41, Died 6 (DUD 6)      | 128                 | 59 (RNA 15, IgM 59) | -                             | -                               |
| Bonney et al., 2012 [182] | 3      | ALF 2, Died 2 (DUD 1), PD 1, Ab 1 | 1 + 1 aborted | 1 (RNA 1, IgM 1) | I-HEV 1                        | Recovered, RNA -ve 3 weeks, IgM -ve 4 weeks. |
| Pradhan et al., 2012 [183] | 1      | Fetal HEV-AVH 15 weeks. | 1 | 1 (IgM cord blood, amniotic fluid & serum at birth) | Fetal ascites at 15 weeks pregnancy, resolved in follow up | Healthy baby delivered 38 weeks, LFT normal, IgM +ve |

PF = Pregnant females, ALF = acute liver failure, I-HEV = Icteric hepatitis E virus infection, AI-HEV = Anicteric hepatitis E virus infection, MHN = Massive hepatic necrosis, DIC = disseminated intravascular coagulation, FTD = full term delivery, DUD = mother died with baby undelivered, Ab = abortion, PD = premature delivery, RNA = HEV RNA +ve, IgM = IgM anti-HEV +ve, IgG = IgG anti-HEV +ve, RDS = respiratory distress syndrome. LFT = liver function tests, * = total babies born not known, ** = all deliveries had complicated clinical course, *** = baby developed icterus at 6 weeks of birth.

In a seminal piece of research, mother-to-child transmission of HEV in 10 pregnant women was studied [174]. Two mothers died with babies undelivered. Six of the eight live-born babies showed evidence of HEV infection at birth. HEV RNA was detected in cord and birth blood samples in five, IgM anti-HEV in three and IgG anti-HEV seroconversion in four babies. Two babies died within 24 h from hypothermia and hypoglycemia. A liver biopsy in one baby revealed massive hepatic necrosis. Of the remaining six, one baby had icteric hepatitis and the other three had anicteric hepatitis. In another study, vertical transmission of HEV in 15 of the 19 babies born to HEV-infected pregnant women was studied [175]. Six of these died within first week of life. The remaining nine babies survived and five showed HEV RNA for varying intervals lasting up to 32 weeks. All surviving babies recovered and none developed chronic liver disease. Recently the relationship of severity of disease in 36 pregnant women (HEV-AVH, 20 and HEV-ALF, 16) with the severity of HEV infection in fetuses and newborn babies was evaluated [140]. Babies born to HEV-ALF mothers were more often HEV infected, viremic, and born with severe disease than those with HEV-AVH. DIC in mothers with HEV-ALF occurred exclusively in pregnant women who delivered babies with HEV-ALF. All the six mothers who survived had delivered babies within 4 days (2.3 ± 1.0 days) of onset of encephalopathy. Based on these data, it was postulated that severe fetal disease is the likely cause of increased severity of HEV infection in the mother, akin to the mirror syndrome in pregnancy, and delivery of baby performed early in the course of the disease may reverse the severe maternal disease [184–186].

Vertically transmitted fetal HEV infections and HEV infections in newborn babies have a wide spectrum of manifestations (Figure 4). Severe fetal disease results in intrauterine fetal death, and often the mother also had severe disease with DIC and died before delivery. Autopsies of such fetuses have shown massive hepatic necrosis. A significant proportion with severe disease present with hypothermia, hypoxia, and hypoglycemia at birth and die within 24 to 48 h of birth. Liver biopsies in such patients also show massive hepatic necrosis. Babies born with HEV infection may be asymptomatic with mild abnormality of liver tests (anicteric HEV) or present with jaundice with elevated live tests (Icteric HEV). The disease is self-limiting and serial follow-up reports clinical, serological and virological recovery in few weeks. A few babies show prolonged viremia lasting for up to 32 weeks, with eventual recovery.

8.6. Maternal–Fetal Interface HEV Infections

The role of HEV-gt1 is increasingly being recognized in causing infection and dysregulation at the maternal–fetal interface which leads to vertical transmission and increased systemic inflammation and consequent severe maternal disease [187]. Based on HEV transplacental transmission to the fetus, Bose et al. [188] studied placental HEV replication in 90 pregnant women (HEV-AVH 68 and HEV-ALF 22) and detected replicative HEV RNA and HEV RNA staining by ORF3, which correlated with fetal and maternal mor-
The role of HEV-gt1 is increasingly being recognized in causing infection and dysregulation at the maternal–fetal interface with HEV-gt1 and HEV-gt3 and showed HEV-gt1 was more efficient than HEV-gt3 in viral replication and production and showed more severe tissue damage (necrosis and apoptosis) with upregulated IL-6, CCL-3, and CCL-4 and downregulated CXCL-10 and IFN-γ2/3. The authors concluded that HEV placental replication is genotype-specific and HEV-1 tropism at the maternal–fetal interface along with the extent of tissue damage, pro-inflammatory cytokines, and chemokines might be responsible for the severe maternal disease.

### 9. Management

HEV infection in pregnant women requires a team approach, determined by stage and severity of the disease in the mother, occurrence of obstetrical complications, and severity of vertically transmitted disease in the fetus/neonate.

HEV-AVH is usually a self-limiting disease and needs supportive medical treatment. At the onset, prodromal symptoms are limited to anorexia, fever, nausea, vomiting, and abdominal discomfort and generally subside within a week. A few patients may need a short hospital stay for intravenous fluids given for severe vomiting. Otherwise, patients are advised bed rest at home with bathroom privileges during prodrome and icteric disease. Later, physical activity is restricted and work can be resumed when disease recovery occurs. A portable high caloric diet with high carbohydrate and low fat is usually advised, but has no benefit in disease recovery. Cholestatic symptoms if intractable can be managed with antihistamines, cholestyramine, and/or ursodeoxycholic acid (UDCA). Corticosteroids should not be administered unless there is associated autoimmune hepatitis.

Patients are at high risk for ALF and the disease course can be unpredictable. So, a close watch on impending signs of liver failure (shrinking liver size, high or rising INR, rapid rise in serum bilirubin, and development of ascites or coagulopathy) must be kept.

![Diagram](image-url)

**Figure 4.** Fetal-neonatal hepatitis E virus infection recorded in fetuses and neonates from 72 pregnant women with hepatitis E virus infection seen at Sher-I-Kashmir Institute of Medical Sciences, Srinagar Kashmir, India from Dec 1993 onwards [140,174,175]. ALF = acute liver failure, RNA = HEV RNA, IgM = IgM anti-HEV.
Patients with impending signs of ALF need intensive care management. Management policies to treat complications of ALF, namely encephalopathy, cerebral edema, hypoglycemia, coagulopathy, and possible DIC, GI bleed, sepsis, and renal failure, have been well standardized and should be immediately enforced. Liver transplantation team if available must be involved and considered if prognostic criteria employed are met [134,135,190,191]. Unfortunately, as of today, only isolated case reports of liver transplantation in pregnant women with HEV-ALF are published in the literature [192–194].

A close obstetric watch is needed in both HEV-AVH and HEV-ALF patients to evaluate the stage of pregnancy, fetal wellbeing, and growth. Complications such as abortions, preterm labor, premature rupture of membranes, stillbirth, intrauterine deaths, and increased risk of bleeding associated with coagulopathy can occur and need to be aggressively managed by standard obstetric guidelines [128]. Therapeutic termination of pregnancy and its beneficial effects on liver disease in the mother needs serious consideration [34,195], as events in the maternal–fetal interface and the fetus are involved and are incriminated in the severity of the maternal disease [151,184]. Therapeutic termination has proved effective in two other clinical syndromes, namely HELP syndrome and acute fatty liver in pregnancy, wherein fetal events drive the maternal disease [196,197]. Several investigators do not recommend termination of pregnancy in pregnant women with HEV-ALF [198,199]. This is based on the results of a retrospective study, in which 42 patients with HEV-ALF were studied [200]. Nine of the 22 women who delivered had died along with 14 of the women who continued their pregnancy. There was no significant difference in mortality in the two groups. However, in a subgroup analysis, the authors showed that patients with lesser degree (grade 1–3) of encephalopathy who delivered had lesser mortality (5/16) than those who continued their pregnancy (13/20, \( p < 0.046 \)). Satia and Shilotri [201] from Mumbai, Maharashtra, India showed promising results of induction of labor in a pregnant woman with HEV-ALF with grade 2 hepatic encephalopathy and DIC. After induced vaginal delivery, the patient made an eventual recovery. The authors recommended therapeutic termination of pregnancy in HEV-ALF with lower grades of encephalopathy for a better maternal outcome. We showed that of the 16 pregnant women with HEV-ALF, 10 of whom also had DIC, all the six mothers (DIC in 3) who delivered babies within 4 days (mean ± 1SD 2.3 ± 1.0 days) from onset of encephalopathy and with lower grades of encephalopathy (mean ± 1SD 3.0 ± 0.89) survived. In contrast, all the 10 mothers, of whom six had DIC, who died had delivered babies after 4 days (mean ± 1SD 9.6 ± 3.0 days) and with higher grades of encephalopathy (mean ± 1SD 3.5 ± 0.53) (\( p = 0.02 \)). The results of such an endeavor are striking in sick patients with severe metabolic problems and DIC (Figure 5). Thus, therapeutic or spontaneous termination of pregnancy with HEV-ALF early in the course of disease with lesser grades of encephalopathy was recommended [140].

Randomized trials on the therapeutic role of termination in HEV-ALF pregnant women need to be carried out. However, till the results of such trials are available, it is a safe practice to induce labor early in the course of disease with lower grades of encephalopathy for a better maternal outcome.

Neonatal care is essential as HEV is known to infect the fetus/neonate resulting in considerable fetal and perinatal morbidity and mortality [175].

Several drugs, namely ribavirin, pegylated IFN, and sofosbuvir, inhibit HEV replication, have an antiviral property, and are drugs of choice to manage chronic HEV-3 in solid organ transplant and patients with some hemopoietic malignancies [11]. Recently ribavirin has been successfully used to treat HEV acute-on-chronic-liver-failure and severe HEV infection in nonpregnant states [202]. Ribavirin is teratogenic and is contraindicated during pregnancy and there are no reports of ribavirin therapy in HEV-AVH and HEV-ALF.
Viruses 2021, 13, x 15 of 24

Figure 5. Spontaneous Vaginal Delivery in pregnancy with HEV-ALF and the outcome on maternal disease. A 30-year-old pregnant woman presented with features of icteric hepatitis E virus infection. On the 24th day of her illness, she had rapid deterioration with encephalopathy, cerebral edema, and laboratory features of DIC. She delivered a live baby vaginally with icteric hepatitis E four days after the onset of encephalopathy. Serial follow-up showed rapid clinical improvement in encephalopathy, cerebral edema, and DIC. PSE = portosystemic encephalopathy, CE = cerebral edema, DIC = disseminated intravascular coagulation, RNA = HEV RNA, IgM = IgM anti-HEV, IgG = IgG anti-HEV.

10. Vaccination

The development of the HEV vaccine is seen as a breakthrough in the control of hepatitis E [203,204]. Vaccination against HEV in pregnant women and women of childbearing age in endemic regions may be the most important management strategy [158]. The Chinese vaccine, HEV 239 marketed as Hecolin [205], is protective against HEV-gt1. The vaccine has been shown to be safe in pregnant women [206] and protects against HEV infection and HEV-related adverse outcomes in pregnant rabbits [207]. Recently, a phase IV trial has been initiated to assess the effectiveness, safety, and immunogenicity of the HEV 239 vaccine in women of childbearing age in rural Bangladesh, where HEV infection is endemic [208]. Availability of the vaccine in developing countries is being watched with great interest [209].

Funding: This work was supported by ‘Khuroo’s Medical Trust’, a non-profit organization which supports academic activities, disseminates medical education and helps poor patients for medical treatment.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The author declares no conflict of interest.

Abbreviations

| Acronym | Description                        |
|---------|------------------------------------|
| AVH     | Acute viral hepatitis              |
| HEV     | Hepatitis E virus                  |
| HAV     | Hepatitis A virus                  |
| HCV     | Hepatitis C virus                  |
| NANBH   | non-A, non-B hepatitis             |
| ET-NANBH| Enterically-transmitted non-A, non-B hepatitis |
| PT-NANBH| Parentally-transmitted non-A, non-B hepatitis |
ENANBH  Epidemic non-A, non-B hepatitis
ALF  Acute liver failure
gt  genotype
ORF  Open Reading Frame
CFR  Case fatality rate
DIC  Disseminated intravascular coagulation
VLP  Virus like particles

References
1. Teo, C.G. Fatal outbreaks of jaundice in pregnancy and the epidemic history of hepatitis E. Epidemiol. Infect. 2012, 140, 767–787. [CrossRef]
2. Saint-Vel, O. Note on a form of severe jaundice in pregnant women. Gazette des Hôpitaux Civils et Militaires 1862, 65, 538–539. (In French)
3. Decaisne, E. An epidemic of simple jaundice observed in Paris and in the vicinity. Gazette Hebdomadaire de Médecine et de Chirurgie 1872, 19, 44. (In French)
4. Khuroo, M.S.; Khuroo, M.S.; Khuroo, N.S. Transmission of Hepatitis E Virus in Developing Countries. Indian J. Gastroenterol. 2011, 30, 373–378. [CrossRef]
5. Skidmore, S.J.; Yarbough, P.O.; Gabor, K.A.; Reyes, G.R. Hepatitis E virus: The cause of a waterborne hepatitis outbreak. Viruses 2021, 13, 1329. [CrossRef]
6. Adams, R.H.; Combes, B. Viral Hepatitis During Pregnancy. JAMA J. Am. Med. Assoc. 1945, 132, 252–255. [CrossRef]
7. Yarbough, P.O.; Tam, A.W.; Fry, K.E.; Krawczynski, K.; McCaustland, K.A.; Bradley, D.W.; Reyes, G.R. Hepatitis E virus: New insights into an old disease. Intervirology 1989, 32, 120–131. [CrossRef]
8. Holzbach, R.T. Jaundice in pregnancy—1976. Am. J. Med. 1977, 62, 105–115. [CrossRef]
9. Wahi, P.N.; Arora, M.M. Epidemic hepatitis. N. Engl. J. Med. 1952, 248, 31–39. [CrossRef]
10. Cahill, K.M. Hepatitis in pregnancy. Obstet. Gynecol. 1957, 10, 473–482. [CrossRef]
11. Yarbough, P.O.; Tam, A.W.; Guerra, M.E.; Huang, C.C.; Bradley, D.W.; Fry, K.E.; Reyes, G.R. Hepatitis E virus (HEV): Molecular cloning and sequencing of the full-length viral genome. Virology 1991, 185, 120–131. [CrossRef]
12. Cossart, Y.E. The outcome of hepatitis B virus infection in pregnancy. Postgrad. Med. J. 1983, 59, 395–401. [CrossRef]
13. Haemmerli, U.P. Jaundice during pregnancy. World J. Gastroenterol. 2005, 11, 323–328. [CrossRef]
14. Naidu, S.S.; Viswanathan, R. Infectious hepatitis in pregnancy during Delhi epidemic. Indian J. Med. Res. 1957, 45, 71–76. [CrossRef]
15. Malkani, P.K.; Grewal, A.K. Observations on infectious hepatitis in pregnancy. J. Clin. Exp. Hepatol. 2014, 4, 281–286. [CrossRef]
16. Decaisne, E. An epidemic of simple jaundice observed in Paris and in the vicinity. Gazette Hebdomadaire de Médecine et de Chirurgie 1872, 19, 44. (In French)
17. Borhanmanesh, F.; Haghighi, P.; Hekmat, K.; Rezaizadeh, K.; Ghavami, A.G. Viral Hepatitis During Pregnancy: Severity and effect on gestation. Gastroenterology 1973, 64, 304–312. [CrossRef]
18. Saint-Vel, O. Note on a form of severe jaundice in pregnant women. Gazette des Hôpitaux Civils et Militaires 1862, 65, 538–539. (In French)
19. Decaisne, E. An epidemic of simple jaundice observed in Paris and in the vicinity. Gazette Hebdomadaire de Médecine et de Chirurgie 1872, 19, 44. (In French)
20. Kamili, S.; Guides, S.; Khuroo, M.S.; Jameel, S.; Salahuddin, M. Hepatitis E: Studies on Transmission, Etiological Agent and Disease. Intervirology 1989, 32, 120–131. [CrossRef]
21. Khuroo, M.; Saleem, M.; Teli, M.; Sofi, M. Failure to detect chronic liver disease after epidemic non-A, non-B hepatitis. Indian J. Med. Res. 1957, 11, 77–84. [CrossRef]
22. Choo, Q.L.; Kuo, G.; Houghton, M. Identification of type-common epitopes. J. Virol. 1989, 63, 651–659. [CrossRef]
23. Malani, A.; Sobh, M.; Chaudhry, A.; Arora, M.; Khuroo, M.S. Spectrum of hepatitis E virus infection in India. J. Med. Virol. 2000, 61, 604–612. [CrossRef]
24. Reyes, G.R.; Purdy, M.A.; Kim, J.P.; Luuk, K.C.; Young, L.M.; Fry, K.E.; Bradley, D.W. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244, 359–362. [CrossRef]
25. Tam, A.W.; Smith, M.M.; Guerra, M.E.; Huang, C.C.; Bradley, D.W.; Fry, K.E.; Reyes, G.R. Hepatitis E virus (HEV): Molecular cloning and sequencing of the full-length viral genome. Virology 1991, 185, 120–131. [CrossRef]
26. Choo, Q.L.; Kuo, G.; Weiner, A.J.; Overby, L.R.; Bradley, D.W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244, 359–362. [CrossRef]
27. Balkan, K.; Kolar, J.; Zaharieva, M.; Aquate, P.; Golya, M. Hepatitis E virus infection in the Balkans: A case-control study. J. Med. Virol. 2010, 82, 1392–1399. [CrossRef]
28. Khuroo, M.S.; Khuroo, M.S.; Khuroo, N.S. Transmission of Hepatitis E Virus in Developing Countries. Indian J. Gastroenterol. 2011, 30, 373–378. [CrossRef]
29. Khuroo, M.S.; Khuroo, M.S.; Khuroo, N.S. Transmission of Hepatitis E Virus in Developing Countries. Indian J. Gastroenterol. 2011, 30, 373–378. [CrossRef]
30. Khuroo, M.S.; Khuroo, M.S.; Khuroo, N.S. Transmission of Hepatitis E Virus in Developing Countries. Indian J. Gastroenterol. 2011, 30, 373–378. [CrossRef]
Viruses 2021, 13, 1329

33. Panda, S.K.; Nanda, S.K.; Zafrullah, M.; Ansari, I.H.; Ozdener, M.H.; Jameel, S. An Indian strain of hepatitis E virus (HEV): Cloning, sequence, and expression of structural region and antibody responses in sera from individuals from an area of high-level HEV endemicity. J. Clin. Microbiol. 1995, 33, 2653–2659. [CrossRef]

34. Khuroo, M.S. A Review of Acute Viral Hepatitis E Including Hepatitis E. In Viral Hepatitis: Acute Hepatitis; Ozaras, R., Arends, J.E., Eds.; Springer: Berlin/Heidelberg, Germany, 2019; pp. 77–107.

35. Purdy, M.A.; Harrison, T.J.; Jameel, S.; Meng, X.J.; Okamoto, H.; Van der Poel, W.H.M.; Smith, D.B.; Ictv Report, C. ICTV Virus Taxonomy Profile: Hepeviridae. J. Gen. Virol. 2017, 98, 2645–2646. [CrossRef] [PubMed]

36. Mori, Y.; Matsuura, Y. Structure of hepatitis E viral particle. Virus Res. 2011, 161, 59–64. [CrossRef]

37. Smith, D.B.; Simmonds, P.; Jameel, S.; Emerson, S.U.; Harrison, T.J.; Meng, X.J.; Okamoto, H.; Van der Poel, W.H.; Purdy, M.A. Consensus proposals for classification of the family Hepeviridae. J. Gen. Virol. 2014, 95, 2223–2232. [CrossRef]

38. Yadav, K.K.; Boley, P.A.; Fritts, Z.; Kenney, S.P. Ectopic Expression of Genotype 1 Hepatitis E Virus ORF4 Increases Genotype 3 HEV Viral Replication in Cell Culture. Viruses 2021, 13, 75. [CrossRef] [PubMed]

39. Nair, V.P.; Anang, S.; Subramani, C.; Madhvi, A.; Bakshi, K.; Srivastava, A.; Shalimar; Nayak, B.; Ranjith Kumar, C.T.; Surjit, M. Endoplasmic Reticulum Stress Induced Synthesis of a Novel Viral Factor Mediates Efficient Replication of Genotype-1 Hepatitis E Virus. PLoS Pathog. 2016, 12, e1005521. [CrossRef]

40. Nan, Y.; Zhang, Y.J. Molecular Biology and Infection of Hepatitis E Virus. Front. Microbiol. 2016, 7, 1419. [CrossRef]

41. Primadharshini, P.P.; Nagashima, S.; Okamoto, H. Genetic Variability and Evolution of Hepatitis E Virus. Viruses 2019, 11, 456. [CrossRef]

42. Meng, X.J. Hepatitis E virus: Animal reservoirs and zoonotic risk. Vet. Microbiol. 2010, 140, 256–265. [CrossRef]

43. Sridhar, S.; Teng, J.L.L.; Chiu, T.-H.; Lau, S.K.P.; Woo, P.C.Y. Hepatitis E Virus Genotypes and Evolution: Emergence of Camel Hepatitis E Variants. Int. J. Mol. Sci. 2017, 18, 869. [CrossRef]

44. Sridhar, S.; Yip, C.C.Y.; Wu, S.; Cai, J.; Zhang, A.-J.-X.; Leung, K.-H.; Chung, T.W.H.; Chan, J.F.W.; Chan, W.-M.; Teng, J.L.L.; et al. Rat Hepatitis E Virus as Cause of Persistent Hepatitis after Liver Transplant. Emerg. Infect. Dis. 2018, 24, 2241–2250. [CrossRef]

45. Sridhar, S.; Yip, C.C.; Wu, S.; Chew, N.F.; Leung, K.H.; Chan, J.F.; Zhao, P.S.; Chan, W.M.; Poon, R.W.; Tsoi, H.W.; et al. Transmission of Rat Hepatitis E Virus Infection to Humans in Hong Kong: A Clinical and Epidemiological Analysis. Hepatology 2021, 73, 10–22. [CrossRef]

46. El-Mokhtar, M.A.; Elkhawaga, A.A.; Sayed, I.M. Assessment of hepatitis E virus (HEV) in the edible goat products pointed out a risk for human infection in Upper Egypt. Int. J. Food Microbiol. 2020, 330, 108784. [CrossRef]

47. Rein, D.B.; Stevens, G.; Theaker, J.; Wittenborn, J.S.; Wiersma, S.T. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012, 55, 988–997. [CrossRef]

48. Romanò, L.; Paladini, S.; Zanetti, A.R. Hepatitis E: A puzzling double-faced disease. Ann. Ig. 2013, 25, 169–180. [CrossRef] [PubMed]

49. Teshale, E.H.; Hu, D.J.; Holmberg, S.D. The two faces of hepatitis E virus. Clin. Infect. Dis. 2010, 51, 328–334. [CrossRef] [PubMed]

50. Sayed, I.M.; El-Mokhtar, M.A.; Mahmoud, M.A.R.; Elkhawaga, A.A.; Gaber, S.; Seddek, N.H.; Abdel-Wahid, L.; Ashmawy, A.M.; Alkareemy, E.A.R. Clinical Outcomes and Prevalence of Hepatitis E Virus (HEV) Among Non-A-C Hepatitis Patients in Egypt. Infect. Drug Resist. 2021, 14, 59–69. [CrossRef]

51. El-Mokhtar, M.A.; Karam-Allah Ramadan, H.; Abdel Hameed, M.R.; Kamel, A.M.; Mandour, S.A.; Ali, M.; Abdel-Malek, M.A.Y.; El-Kareem, D.M.A.; Adel, S.; Salama, E.H.; et al. Evaluation of hepatitis E antigen kinetics and its diagnostic utility for prediction of the outcomes of hepatitis E type 1 infection. Virulence 2021, 12, 1334–1344. [CrossRef]

52. El-Mokhtar, M.A.; Seddik, M.I.; Osman, A.O.B.; Mahmoud, A.A.; Mandour, S.A.; Radwan, E.; Ali, M.; Ismael, A.E.; Twisy, H.O.; Karam-Allah Ramadan, H.; et al. None of HEV genotype 1 infections harming the male reproductive system. Virology 2021, 554, 37–41. [CrossRef] [PubMed]

53. Stoszek, S.K.; Engle, R.E.; Abdal-Hamid, M.; Mikhail, N.; Abdal-Aziz, F.; Medhat, A.; Fix, A.D.; Emerson, S.U.; Purcell, R.H.; Strickland, G.T. Hepatitis E antibody seroconversion without disease in highly endemic rural Egyptian communities. Trans. R. Soc. Trop. Med. Hyg. 2006, 100, 89–94. [CrossRef]

54. Stoszek, S.K.; Abdal-Hamid, M.; Saleh, D.A.; El Kafrawy, S.; Narooz, S.; Hawash, Y.; Shebl, F.M.; El Daly, M.; Said, A.; Kassem, E.; et al. High prevalence of hepatitis E antibodies in pregnant Egyptian women. Trans. R. Soc. Trop. Med. Hyg. 2006, 100, 95–101. [CrossRef] [PubMed]

55. Sayed, I.M.; Hammam, A.R.A.; Elfaruk, M.S.; Alsaleem, K.A.; Gaber, M.A.; Ezzat, A.A.; Salama, E.H.; Elkhawaga, A.A.; El-Mokhtar, M.A. Enhancement of the Molecular and Serological Assessment of Hepatitis E Virus in Milk Samples. Microorganisms 2020, 8, 1231. [CrossRef] [PubMed]

56. Sayed, I.M.; Elkhawaga, A.A.; El-Mokhtar, M.A. Circulation of hepatitis E virus (HEV) and/or HEV-like agent in Egyptian farms could represent a potential source of infection for Egyptian people. Int. J. Food Microbiol. 2020, 317, 108479. [CrossRef] [PubMed]

57. Shata, M.T.; Daef, E.A.; Zaki, M.E.; Abdelwahab, S.F.; Marzuuk, N.M.; Sobhy, M.; Rafaat, M.; Abdelbaki, L.; Nafeh, M.A.; Hashem, M.; et al. Protective role of humoral immune responses during an outbreak of hepatitis E in Egypt. Trans. R. Soc. Trop. Med. Hyg. 2012, 106, 613–618. [CrossRef] [PubMed]

58. Arankalle, V.A.; Chadha, M.S.; Tsarev, S.A.; Emerson, S.U.; Rishbud, A.R.; Banerjee, K.; Purcell, R.H. Seroepidemiology of water-borne hepatitis in India and evidence for a third enterically-transmitted hepatitis agent. Proc. Natl. Acad. Sci. USA 1994, 91, 3428–3432. [CrossRef] [PubMed]

59. Gupta, N.; Sarangi, A.N.; Dadhich, S.; Dixit, V.K.; Chetri, K.; Goel, A.; Aggarwal, R. Acute hepatitis E in India appears to be caused exclusively by genotype 1 hepatitis E virus. Indian J. Gastroenterol. 2018, 37, 44–49. [CrossRef]
60. Viswanathan, R. Infectious hepatitis in Delhi (1955–1956): A critical study—Epidemiology. Indian J. Med. Res. 1957, 45, 71–76.
61. Wongs, D.C.; Purcell, R.H.; Sreenivasan, M.A.; Prasad, S.R.; Pavri, K.M. Epidemic and endemic hepatitis in India: Evidence for a non-A, non-B hepatitis virus aetiology. Lancet 1980, 2, 876–879. [CrossRef]
62. Naik, S.R.; Aggarwal, R.; Salunke, P.N.; Mehrotra, N.N. A large waterborne viral hepatitis E epidemic in Kanpur, India. Bull. World Health Organ. 1992, 70, 597–604.
63. Tandon, B.N.; Joshi, Y.K.; Jawn, S.J. An epidemic of non-A, non-B hepatitis in north India. Indian J. Med. Res. 1982, 75, 739–744.
64. Sreenivasan, M.A.; Sehgal, A.; Prasad, S.R.; Dhorje, S. A sero-epidemiologic study of a water-borne epidemic of viral hepatitis in Kolhapur City, India. J. Hyg. 1984, 93, 113–122. [CrossRef] [PubMed]
65. Arankalle, V.A.; Paranji, S.; Emerson, S.U.; Purcell, R.H.; Walfme, A.M. Phylogenetic analysis of hepatitis E virus isolates from India (1976–1993). J. Gen. Virol. 1999, 80, 1691–1700. [CrossRef] [PubMed]
66. Rab, M.A.; Bile, M.K.; Mubarak, M.M.; Asghar, H.; Sami, Z.; Siddiqui, S.; Dil, A.S.; Barzgar, M.A.; Chaudhry, M.A.; Burney, M.I. Water-borne hepatitis E virus epidemic in Islamabad, Pakistan: A common source outbreak traced to the malfunction of a modern water treatment plant. Am. J. Trop. Med. Hyg. 1997, 57, 151–157. [CrossRef]
67. Tsareva, S.A.; Emerson, S.U.; Reyes, G.R.; Tsareva, T.S.; Legters, L.J.; Malik, I.A.; Iqbal, M.; Purcell, R.H. Characterization of a prototype strain of hepatitis E virus. Proc. Natl. Acad. Sci. USA 1992, 89, 559–563. [CrossRef] [PubMed]
68. He, J. Molecular detection and sequence analysis of a new hepatitis E virus isolate from Pakistan. J. Viral Hepat. 2006, 13, 840–844. [CrossRef]
69. Hla, M.; Myint Myint, S.; Tun, K.; Thein-Maung, M.; Khin Maung, T. A clinical and epidemiological study of an epidemic of non-A non-B hepatitis in Rangoon. Am. J. Trop. Med. Hyg. 1985, 34, 1183–1189. [CrossRef]
70. Kane, M.A.; Bradley, D.W.; Shrestha, S.M.; Maynard, J.E.; Cook, E.H.; Mishra, R.P.; Joshi, D.D. Epidemic non-A, non-B hepatitis in Nepal. Recovery of a possible etiologic agent and transmission studies in marmosets. JAMA 1984, 252, 3140–3145. [CrossRef] [PubMed]
71. Gouvea, V.; Snellings, N.; Popek, M.J.; Longer, C.F.; Innis, B.L. Hepatitis E virus: Complete genome sequence and phylogenetic analysis of a Nepali isolate. Virus Res. 1998, 57, 21–26. [CrossRef]
72. Shrestha, S.M. Hepatitis E in Nepal. Kathmandu Univ. Med. J. KUMJ 2006, 4, 530–544. [PubMed]
73. International Centre for Diarrhoeal Disease Research, Bangladesh. Outbreak of hepatitis E in a low income urban community in Bangladesh. Health Sci. Bull. 2009, 7, 14–20.
74. Sugitani, M.; Tamura, A.; Shimizu, Y.K.; Sheikh, A.; Kinukawa, N.; Shimizu, K.; Moriyama, M.; Komiyama, K.; Li, T.C.; Takeda, N.; et al. Detection of hepatitis E virus RNA and genotype in Bangladesh. J. Gastroenterol. Hepatol. 2009, 24, 599–604. [CrossRef] [PubMed]
75. Haque, F.; Banu, S.S.; Ara, K.; Chowdhury, I.A.; Chowdhury, S.A.; Kamili, S.; Rahman, M.; Luby, S.P. An outbreak of hepatitis E in an urban area of Bangladesh. J. Viral Hepat. 2015, 22, 948–956. [CrossRef] [PubMed]
76. Albetkova, A.; Drobeniuc, J.; Yashina, T.; Musabaev, E.; Robertson, B.; Nainan, O.; Favorov, M. Characterization of hepatitis E virus from outbreak and sporadic cases in Turkmenistan. J. Med. Virol. 2007, 79, 1696–1702. [CrossRef]
77. Shakhlig’dian, I.V.; Khukhlovich, P.A.; Kuzin, S.N.; Favorov, M.O.; Nedachin, A.E. Epidemiological characteristics of non-A, non-B viral hepatitis with a fecal-oral transmission mechanism. Vopr. Virusol. 1986, 31, 175–179.
78. Sharapov, M.B.; Favorov, M.O.; Yashina, T.L.; Brown, M.S.; Onischenko, G.G.; Margolis, H.S.; Chorba, T.L. Acute viral hepatitis morbidity and mortality associated with hepatitis E virus infection: Uzbekistan surveillance data. BMC Infect. Dis. 2009, 9, 35. [CrossRef]
79. Chatterjee, R.; Tsarev, S.; Pillot, J.; Coursaget, P.; Emerson, S.U.; Purcell, R.H. African strains of hepatitis E virus that are distinct from Asian strains. J. Med. Virol. 1997. [CrossRef]
80. Cao, X.-Y.; Ma, X.-Z.; Liu, Y.-Z.; Jin, X.-M.; Gao, Q.; Dong, H.-J.; Zhuang, H.; Liu, C.-B.; Wang, G.-M. Epidemiological and etiological studies on enterically transmitted non-A non-B hepatitis in the south part of Xinjiang. Chin. J. Exp. Clin. Virol. 1989, 3, 1–10. (In Chinese)
81. Aye, T.T.; Uchida, T.; Ma, X.Z.; Iida, F.; Shikata, T.; Zhuang, H.; Win, K.M. Complete nucleotide sequence of a hepatitis E virus isolated from the Xinjiang epidemic (1986–1988) of China. Nucleic Acids Res. 1992, 20, 3512. [CrossRef]
82. Corwin, A.; Jarot, K.; Lubis, I.; Nasution, K.; Suparmawo, S.; Sumardiati, A.; Widodo, S.; Nazir, S.; Orndorff, G.; Choi, Y.; et al. Two years’ investigation of epidemic hepatitis E virus transmission in West Kalimantan (Borneo), Indonesia. Trans. R. Soc. Trop. Med. Hyg. 1995, 89, 262–265. [CrossRef]
83. van Cuyck-Gandre, H.; Zhang, H.Y.; Tsarev, S.A.; Clements, N.J.; Cohen, S.J.; Caudill, J.D.; Buisson, Y.; Coursaget, P.; Warren, R.L.; Longer, C.F. Characterization of hepatitis E virus (HEV) from Algeria and Chad by partial genome sequence. J. Med. Virol. 1997, 53, 340–347. [CrossRef]
84. Belabbes, E.H.; Bouguermouh, A.; Benatallah, A.; Illoul, G. Epidemic non-A, non-B viral hepatitis in Algeria: Strong evidence for its spreading by water. J. Med. Virol. 1985, 16, 257–263. [CrossRef] [PubMed]
85. Boccia, D.; Guttman, J.P.; Klovstad, H.; Hamid, N.; Tatay, M.; Giglnecki, I.; Nizou, J.Y.; Nicand, E.; Guerin, P.J. High mortality associated with an outbreak of hepatitis E virus among displaced persons in Darfur, Sudan. Clin. Infect. Dis. 2006, 42, 1679–1684. [CrossRef] [PubMed]
86. Elduma, A.H.; Zein, M.M.; Karlsson, M.; elkhirid, I.M.; Norder, H. A Single Lineage of Hepatitis E Virus Causes Both Outbreaks and Sporadic Hepatitis in Sudan. Viruses 2016, 8, 273. [CrossRef] [PubMed]
113. van Cuyck, H.; Juge, F.; Roques, P. Phylogenetic analysis of the first complete hepatitis E virus (HEV) genome from Africa. FEMS Immunol. Med. Microbiol. 2003, 39, 133–139. [CrossRef]

114. Rioche, M.; Dubreuil, P.; Kouassi-Samgare, A.; Akran, V.; Nordmann, P.; Pillot, J. Incidence of sporadic hepatitis E in Ivory Coast based on still problematic serology. Bull. World Health Organ. 1997, 75, 349–354.

115. Byskov, J. An outbreak of suspected water-borne epidemic non-A non-B hepatitis in northern Botswana with a high prevalence of hepatitis B carriers and hepatitis delta markers among patients. Trans. R. Soc. Med. Hyg. 1989, 83, 110–116. [CrossRef]

116. Mushahwar, I.K.; Dawson, G.J.; Bile, K.M.; Magnus, L.O. Serological studies of an enterically transmitted non-A, non-B hepatitis in Somalia. J. Med. Virol. 1993, 40, 218–221. [PubMed]

117. Howard, C.M.; Handzel, T.; Hill, V.R.; Grytdal, S.P.; Blanton, C.; Kamili, S.; Drobeniuc, J.; Hu, D.; Teshale, E. Novel risk factors associated with hepatitis E virus infection in a large outbreak in northern Uganda: Results from a case-control study and environmental analysis. Am. J. Trop. Med. Hgy. 2010, 83, 1170–1173. [CrossRef] [PubMed]

118. Anty, R.; Ollier, L.; Peron, J.M.; Nicand, E.; Cannavo, I.; Bongain, A.; Giordanengo, V.; Tran, A. First case report of an acute genotype 3 hepatitis E infected pregnant woman living in South-Eastern France. J. Clin. Virol. 2012, 54, 76–78. [CrossRef] [PubMed]

119. Tabatabai, J.; Wenzel, J.J.; Soboletzki, M.; Flux, C.; Navid, M.H.; Schnitzler, P. First case report of an acute hepatitis E subgenotype 3c infection during pregnancy in Germany. J. Clin. Virol. 2014, 61, 170–172. [CrossRef]

120. Said, B.; Ijaz, S.; Kafatos, G.; Booth, L.; Thomas, H.L.; Walsh, A.; Ramsay, M.; Morgan, D.; Hepatitis, E.I.I.T. Hepatitis E outbreak in south-western Italy: A case-control study. Emerg. Infect. Dis. 2009, 15, 1738–1744. [CrossRef] [PubMed]

121. Clemente-Casares, P.; Ramos-Romero, C.; Ramirez-Gonzalez, E.; Mas, A. Hepatitis E Virus in Industrialized Countries: The Silent Threat. Biomed. Res. Int. 2016, 2016, 9838041. [CrossRef]

122. Ahn, H.S.; Han, S.H.; Kim, Y.H.; Park, B.J.; Kim, D.H.; Lee, J.B.; Park, S.Y.; Song, C.S.; Lee, S.W.; Choi, C.; et al. Adverse fetal outcomes in pregnant rabbits experimentally infected with rabbit hepatitis E virus. Virolology 2017, 512, 187–193. [CrossRef]

123. Lin, S.; Zhang, Y.-J. Advances in Hepatitis E Virus Biology and Pathogenesis. Viruses 2021, 13, 267. [CrossRef]

124. Xia, J.; Liu, L.; Wang, L.; Zhang, Y.; Zeng, H.; Liu, P.; Zou, Q.; Wang, L.; Zhuang, H. Experimental infection of pregnant rabbits with hepatitis E virus demonstrating high mortality and vertical transmission. J. Viral Hepat. 2015, 22, 850–857. [CrossRef]

125. Khuroo, M.S.; Duermeyer, W.; Zargar, S.A.; Ahanger, M.A.; Shah, M.A. Acute sporadic non-A, non-B hepatitis in India. Am. J. Epidemiol. 1983, 118, 360–364. [CrossRef]

126. Khuroo, M.S.; Kamali, S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J. Viral Hepat. 2003, 10, 61–69. [CrossRef]

127. Nayak, N.C.; Panda, S.K.; Datta, R.; Zuckerman, A.J.; Guha, D.K.; Madanagopalan, N.; Buckshee, K. Aetiology and outcome of acute viral hepatitis in pregnancy. J. Gastroenterol. Hepatol. 1989, 4, 345–352. [CrossRef]

128. Patra, S.; Kumar, A.; Trivedi, S.S.; Puri, M.; Sarin, S.K. Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. Ann. Intern. Med. 2007, 147, 28–33. [CrossRef]

129. Jaiswal, S.P.; Jain, A.K.; Naik, G.; Soni, N.; Chitnis, D.S. Viral hepatitis during pregnancy. Int. J. Gynaecol. Obstet. 2001, 72, 103–108. [CrossRef]

130. Beniwal, M.; Kumar, A.; Kar, P.; Jilani, N.; Sharma, J.B. Prevalence and severity of acute viral hepatitis and fulminant hepatitis during pregnancy: A prospective study from north India. Indian J. Med. Microbiol. 2003, 21, 184–185. [CrossRef]

131. Rasheed, C.A.; Navaneethan, U.; Jayanthi, V. Liver disease in pregnancy and its influence on maternal and fetal mortality: A prospective study from Chennai, Southern India. Eur. J. Gastroenterol. Hepatol. 2008, 20, 362–364. [CrossRef]

132. Kar, P.; Budhiraja, S.; Narang, A.; Chakravarthy, A. Etiology of sporadic acute and fulminant non-A, non-B viral hepatitis in north India. Indian J. Gastroenterol. 1997, 16, 43–45. [CrossRef]

133. Arankalle, V.A.; Chobe, L.P.; Joshi, M.V.; Chadha, M.S.; Kundu, B.; Walimbe, A.M. Human and swine hepatitis E viruses from Western India belong to different genotypes. J. Hepatol. 2002, 36, 417–425. [CrossRef]

134. Khuroo, M.S.; Kamali, S. Aetiology and prognostic factors in acute liver failure in India. J. Viral Hepat. 2003, 10, 224–231. [CrossRef]

135. Acharya, S.K.; Dasarathy, S.; Kumer, T.L.; Sushama, S.; Prasanna, K.S.; Tandon, A.; Sreenivas, V.; Nijhawan, S.; Panda, S.K.; Nanda, S.K.; et al. Fulminant hepatitis in a tropical population: Clinical course, cause, and early predictors of outcome. Hepatology 1996, 23, 1448–1455. [CrossRef]

136. Bhatia, V.; Singh, A.; Panda, S.K.; Acharya, S.K. A 20-year single-center experience with acute liver failure during pregnancy: Is the prognosis really worse? Hepatology 2008, 48, 1577–1585. [CrossRef]

137. Karn, R.; Hazam, R.K.; Borkakoti, J.; Kumar, A.; Kar, P. A 5-year Single-Center Experience of Hepatitis E Virus Infection during Pregnancy. J. Clin. Exp. Hepatol. 2020, 10, 135–138. [CrossRef]

138. Kar, P.; Jilani, N.; Husain, S.A.; Pasha, S.T.; Anand, R.; Rai, A.; Das, B.C. Does hepatitis E viral load and genotypes influence the final outcome of acute liver failure during pregnancy? Am. J. Gastroenterol. 2008, 103, 2495–2501. [CrossRef]

139. Acharya, S.K.; Panda, S.K.; Saxena, A.; Gupta, S.D. Acute hepatic failure in India: A perspective from the East. J. Gastroenterol. Hepatol. 2000, 15, 473–479. [CrossRef]

140. Khuroo, M.S.; Kamali, S. Association of severity of hepatitis E virus infection in the mother and vertically transmitted infection in the fetus. Jk Pratct. 2006, 13, 70–74. [CrossRef]

141. Bernuau, J.; Nicand, E.; Durand, F. Hepatitis E-associated acute liver failure in pregnancy: An Indian puzzle. Hepatology 2008, 48, 1380–1382. [CrossRef]

142. Khuroo, M.S. Acute liver failure in India. Hepatology 1997, 26, 244–246. [CrossRef]

143. Cornet, L.; Banda, D.H.; Meuleman, P. Animal Models for Hepatitis E virus. Viruses 2019, 11, 564. [CrossRef]
144. Tsarev, S.A.; Tsareva, T.S.; Emerson, S.U.; Rippy, M.K.; Zack, P.; Shapiro, M.; Purcell, R.H. Experimental hepatitis E in pregnant rhesus monkeys: Failure to transmit hepatitis E virus (HEV) to offspring and evidence of naturally acquired antibodies to HEV. J. Infect. Dis. 1995, 172, 31–37. [CrossRef]

145. Arankalle, V.A.; Chadha, M.S.; Banerjee, K.; Srinivasan, M.A.; Chobe, L.P. Hepatitis E virus infection in pregnant rhesus monkeys. Indian J. Med. Res. 1993, 97, 4–8.

146. Sayed, I.M.; Seddik, M.I.; Gaber, M.A.; Saber, S.H.; Mandour, S.A.; El-Mokhtar, M.A. Replication of Hepatitis E Virus (HEV) in Pregnant BALB/c Mice. Viruses 2019, 11, 451. [CrossRef] [PubMed]

147. Yang, C.; Hao, X.; Li, Y.; Long, F.; He, Q.; Huang, F.; Yu, W. Successful Establishment of Hepatitis E Virus Infection in Pregnant Rhesus Monkeys: Failure to Transmit HEV to Offspring and Evidence of Naturally Acquired Antibodies to HEV. Sci. Rep. 2020, 10, 17517. [CrossRef] [PubMed]

148. Cheng, X.; Wang, S.; Dai, X.; Shi, C.; Wen, Y.; Zhu, M.; Zhan, S.; Meng, J. Rabbit as a novel animal model for hepatitis E virus infection and vaccine evaluation. PLoS ONE 2012, 7, e51616. [CrossRef]

149. El-Mokhtar, M.A.; Sayed, I.M. Model systems for studying extrahepatic pathogenesis of hepatitis E virus. Current knowledge and future directions. Rev. Med. Virol. 2021, 2218. [CrossRef] [PubMed]

150. Terrault, N.A.; Levy, M.T.; Cheung, K.W.; Jourdain, G. Viral hepatitis and pregnancy. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 117–130. [CrossRef] [PubMed]

151. Gouilly, J.; Chen, Q.; Siewiera, J.; Cartron, G.; Levy, C.; Dubois, M.; Al-Daccak, R.; Izopet, J.; Jabrane-Ferrat, N.; El Costa, H. Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface. Nat. Commun. 2018, 9, 4748. [CrossRef]

152. Borkakoti, J.; Hazam, R.K.; Mohammad, A.; Kumar, A.; Kar, P. Does high viral load of hepatitis E virus influence the severity and prognosis of acute liver failure during pregnancy? J. Med. Virol. 2013, 85, 620–626. [CrossRef]

153. Devhare, P.; Sharma, K.; Mhanddar, V.; Arankalle, V.; Lole, K. Analysis of helicase domain mutations in the hepatitis E virus derived from patients with fulminant hepatic failure: Effects on enzymatic activities and virus replication. Viruses Res. 2014, 184, 103–110. [CrossRef]

154. Cornish, E.F.; Filipovic, I.; Äsenius, F.; Williams, D.J.; McDonnell, T. Innate Immune Responses to Acute Viral Infection during Pregnancy. Front. Immunol. 2020, 11, 572567. [CrossRef] [PubMed]

155. Yang, C.; Yu, W.; Bi, Y.; Long, F.; Li, Y.; Wei, D.; Hao, X.; Situ, J.; Zhao, Y.; Huang, F. Increased oestradiol in hepatitis E virus-infected pregnant women promotes viral replication. J. Viral Hepat. 2018, 25, 742–751. [CrossRef] [PubMed]

156. Mor, G.; Cardenas, I. The immune system in pregnancy: A unique complexity. Am. J. Reprod. Immunol. 2010, 63, 425–433. [CrossRef] [PubMed]

157. Wang, W.; Sung, N.; Gilman-Sachs, A.; Kwak-Kim, J. T Helper (Th) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells. Front. Immunol. 2020, 11, [CrossRef]

158. Wu, C.; Wu, X.; Xia, J. Hepatitis E virus infection during pregnancy. Viral J. 2020, 17, 73. [CrossRef] [PubMed]

159. Devi, S.G.; Kumar, A.; Kar, P.; Husain, S.A.; Sharma, S. Association of pregnancy outcome with cytokine gene polymorphisms in HEV infection during pregnancy. J. Med. Virol. 2014, 86, 1366–1376. [CrossRef] [PubMed]

160. Kumar, A.; Devi, S.G.; Kar, P.; Agarwal, S.; Husain, S.A.; Gupta, R.K.; Sharma, S. Association of cytokines in hepatitis E with pregnancy outcome. Cytokine 2014, 65, 95–104. [CrossRef] [PubMed]

161. Jilani, N.; Das, B.C.; Husain, S.A.; Baweja, U.K.; Chattopadhy, D.; Gupta, R.K.; Sardana, S.; Kar, P. Hepatitis E virus infection and fulminant hepatic failure during pregnancy. J. Gastroenterol. Hepatol. 2007, 22, 676–682. [CrossRef]

162. Wu, J.; Guo, Y.; Lu, X.; Huang, F.; Lv, F.; Wei, D.; Shang, A.; Yang, J.; Pan, Q.; Jiang, B.; et al. Th1/Th2 Cells and Associated Cytokines in Acute Hepatitis E and Related Acute Liver Failure. J. Immunol. Res. 2020, 2020, 6027361. [CrossRef]

163. Pal, R.; Aggarwal, R.; Naik, S.R.; Das, V.; Das, S.; Naik, S. Immunological alterations in pregnant women with acute hepatitis E. J. Gastroenterol. Hepatol. 2005, 20, 1094–1101. [CrossRef]

164. Prusty, B.K.; Hedau, S.; Singh, A.; Kar, P.; Das, B.C. Selective suppression of NF-kBp65 in hepatitis virus-infected pregnant women manifesting severe liver damage and high mortality. Mol. Med. 2007, 13, 518–526. [CrossRef]

165. Jung, S.; Seo, D.J.; Yeo, D.; Wang, Z.; Min, A.; Zhao, Z.; Song, M.; Choi, I.S.; Myoung, J.; Choi, C. Experimental infection of hepatitis E virus induces pancreatic necrosis in miniature pigs. Sci. Rep. 2020, 10, 12022. [CrossRef]

166. Sayed, I.M.; Seidid, M.I.; Gaber, M.A.; Saber, S.H.; Mandour, S.A.; El-Mokhtar, M.A. Replication of Hepatitis E Virus (HEV) in Primary Human-Derived Monocytes and Macrophages In Vitro. Vaccines 2020, 8, 239. [CrossRef]

167. Kumar, P.; Magon, N. Hormones in pregnancy. Niger Med. J. 2012, 53, 179–183. [CrossRef]

168. Robinson, D.P.; Klein, S.L. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm. Behav. 2012, 62, 263–271. [CrossRef]

169. Bi, Y.; Yang, C.; Yu, W.; Zhao, X.; Zhao, C.; He, Z.; Jing, S.; Wang, H.; Huang, F. Pregnancy serum facilitates hepatitis E virus replication in vitro. J. Gen. Virol. 2015, 96, 1055–1061. [CrossRef] [PubMed]

170. Berkane, N.; Liere, P.; Oudinet, J.-P.; Hertig, A.; Lefèvre, G.; Pluchino, N.; Schumacher, M.; Chabbert-Buffet, N. From Pregnancy to Preeclampsia: A Key Role for Estrogens. Endocr. Rev. 2017, 38, 123–144. [CrossRef]

171. Bose, P.D.; Das, B.C.; Kumar, A.; Gondal, R.; Kumar, D.; Kar, P. High viral load and deregulation of the progesterone receptor signaling pathway: Association with hepatitis E-related poor pregnancy outcome. J. Hepatol. 2011, 54, 1107–1113. [CrossRef] [PubMed]

172. Park, J.E. Nutrition assessment schedule. In Text Book of Preventive and Social Medicine; Banasidas Bhanot: New Delhi, India, 1974.
173. Krain, L.J.; Atwell, J.E.; Nelson, K.E.; Labrique, A.B. Fetal and neonatal health consequences of vertically transmitted hepatitis E virus infection. *Am. J. Trop. Med. Hag.* 2014, 90, 365–370. [CrossRef]

174. Khuroo, M.S.; Kamili, S.; Jameel, S. Vertical transmission of hepatitis E virus. *Lancet* 1995, 345, 1025–1026. [CrossRef]

175. Khuroo, M.S.; Kamili, S.; Khuroo, M.S. Clinical course and duration of viremia in vertically transmitted hepatitis virus (HEV) infection in babies born to HEV-infected mothers. *J. Viral Hepat.* 2009, 16, 519–523. [CrossRef] [PubMed]

176. Singh, S.; Mohanty, A.; Joshi, Y.K.; Deka, D.; Mohanty, S.; Panda, S.K. Mother-to-child transmission of hepatitis E virus infection. *Indian J. Pediatr.* 2003, 70, 37–39. [CrossRef]

177. Kumar, R.M.; Uduman, S.; Rana, S.; Kochiyl, J.K.; Usmani, A.; Thomas, L. Sero-prevalence and mother-to-infant transmission of hepatitis E virus among pregnant women in the United Arab Emirates. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2001, 100, 9–15. [CrossRef]

178. Khuroo, M.S.; Kamili, S.; Dahab, S.; Yattoo, G.N. Severe fetal hepatitis E virus infection is the possible cause of increased severity of hepatitis E virus infection in the mother: Another example of mirror syndrome. *Am. J. Gastroenterol.* 2004, 99, S100. [CrossRef]

179. Khuroo, M.S.; Khuroo, M.S. Clinical course and duration of viremia in vertically transmitted hepatitis E virus (HEV) infection in babies born to HEV-infected mothers. *J. Viral Hepat.* 2009, 16, 519–523. [CrossRef] [PubMed]

180. Shalimar; Acharya, S.K. Hepatitis E and acute liver failure in pregnancy. *Int. J. Gynecol. Obstet.* 2004, 85, 240–244. [CrossRef]

181. Pradhan, M.; Anand, B.; Singh, A. Hepatitis E Virus Infection Causing Isolated Fetal Ascites: A Case Report. *Fetal Diagn. Ther.* 2012, 32, 292–294. [CrossRef] [PubMed]

182. Bose, P.D.; Das, B.C.; Hazam, R.K.; Kumar, A.; Medhi, S.; Kar, P. Evidence of extrahepatic replication of hepatitis E virus in human placenta. *J. Gen. Virol.* 2014, 95, 1266–1271. [CrossRef] [PubMed]

183. El-Mokhtar, M.A.; Othman, E.R.; Khashbah, M.Y.; Ismael, A.; Ghaliony, M.A.; Seddik, M.I.; Sayed, I.M. Evidence of the extrahepatic replication of Hepatitis E Virus in Human Endometrial Stromal Cells. *Pathogens* 2020, 9, 295. [CrossRef] [PubMed]

184. Shalimar; Acharya, S.K. Hepatitis E and acute liver failure in pregnancy. *Int. J. Gynecol. Obstet.* 2004, 99, S100. [CrossRef]

185. Stadhouders, R.; Abu-Saad, H.H.; O’Carroll, M.R. Fetal and neonatal health consequences of vertically transmitted hepatitis E virus infection. *Fetal Diagn. Ther.* 2012, 32, 292–294. [CrossRef] [PubMed]

186. El Sayed Zaki, M.; El Aal, A.A.; Badawy, A.; El-Deeb, D.R.; El-Kheir, N.Y. Clinicolaboratory study of mother-to-neonate transmission of hepatitis E virus in Egypt. *Ann. Intern. Med.* 2016, 165, 376–383. [CrossRef] [PubMed]

187. Kumar, R.M.; Uduman, S.; Rana, S.; Kochiyl, J.K.; Usmani, A.; Thomas, L. Sero-prevalence and mother-to-infant transmission of hepatitis E virus among pregnant women in the United Arab Emirates. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2001, 100, 9–15. [CrossRef]

188. Khuroo, M.S.; Kamili, S.; Jameel, S. Vertical transmission of hepatitis E virus. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2001, 100, 9–15. [CrossRef]

189. Shalimar; Acharya, S.K. Hepatitis E and acute liver failure in pregnancy. *Int. J. Gynecol. Obstet.* 2004, 85, 240–244. [CrossRef]

190. Bose, P.D.; Das, B.C.; Hazam, R.K.; Kumar, A.; Medhi, S.; Kar, P. Evidence of extrahepatic replication of hepatitis E virus in human placenta. *J. Gen. Virol.* 2014, 95, 1266–1271. [CrossRef] [PubMed]

191. Pradhan, M.; Anand, B.; Singh, A. Hepatitis E Virus Infection Causing Isolated Fetal Ascites: A Case Report. *Fetal Diagn. Ther.* 2012, 32, 292–294. [CrossRef] [PubMed]

192. Bose, P.D.; Das, B.C.; Hazam, R.K.; Kumar, A.; Medhi, S.; Kar, P. Evidence of extrahepatic replication of hepatitis E virus in human placenta. *J. Gen. Virol.* 2014, 95, 1266–1271. [CrossRef] [PubMed]

193. Khuroo, M.S.; Kamili, S.; Dahab, S.; Yattoo, G.N. Severe fetal hepatitis E virus infection is the possible cause of increased severity of hepatitis E virus infection in the mother: Another example of mirror syndrome. *Am. J. Gastroenterol.* 2004, 99, S100. [CrossRef]

194. Shalimar; Acharya, S.K. Hepatitis E and acute liver failure in pregnancy. *Int. J. Gynecol. Obstet.* 2004, 99, S100. [CrossRef]

195. Shalimar; Acharya, S.K. Hepatitis E and acute liver failure in pregnancy. *Int. J. Gynecol. Obstet.* 2004, 99, S100. [CrossRef]

196. Khuroo, M.S.; Kamili, S.; Dahab, S.; Yattoo, G.N. Severe fetal hepatitis E virus infection is the possible cause of increased severity of hepatitis E virus infection in the mother: Another example of mirror syndrome. *Am. J. Gastroenterol.* 2004, 99, S100. [CrossRef]

197. Kumar, R.M.; Uduman, S.; Rana, S.; Kochiyl, J.K.; Usmani, A.; Thomas, L. Sero-prevalence and mother-to-infant transmission of hepatitis E virus among pregnant women in the United Arab Emirates. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2001, 100, 9–15. [CrossRef]

198. Khuroo, M.S.; Kamili, S.; Dahab, S.; Yattoo, G.N. Severe fetal hepatitis E virus infection is the possible cause of increased severity of hepatitis E virus infection in the mother: Another example of mirror syndrome. *Am. J. Gastroenterol.* 2004, 99, S100. [CrossRef]

199. Shalimar; Acharya, S.K. Hepatitis E and acute liver failure in pregnancy. *Int. J. Gynecol. Obstet.* 2004, 99, S100. [CrossRef]

200. Banait, V.S.; Sandur, V.; Parikh, F.; Muruges, M.; Ranka, P.; Ramesh, V.S.; Sasidharan, M.; Sattar, A.; Kamat, S.; Dalal, A.; et al. Outcome of acute liver failure due to acute hepatitis E in pregnant women. *Indian J. Gastroenterol.* 2007, 26, 6–10. [PubMed]

201. Satia, M.; Shilotri, M. Successful maternal and perinatal outcome of hepatitis E in pregnancy with fulminating hepatic failure. *Int. J. Reprod. Contracept. Obstet. Gynecol.* 2016, 5, 2475–2477. [CrossRef]

202. Shrestha, A.; Gupta, B.P.; Lama, T.K. Current Treatment of Acute and Chronic Hepatitis E Virus Infection: Role of Antivirals. *Eur. J. Hepatogastroenterol.* 2017, 7, 73–77. [CrossRef]

203. Zhu, F.C. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: A large-scale, randomised, double-blind placebo-controlled, phase 3 trial. *Lancet* 2010, 376, 895–902. [CrossRef]
204. Zhang, J.; Zhang, X.F.; Huang, S.J.; Wu, T.; Hu, Y.M.; Wang, Z.Z.; Wang, H.; Jiang, H.M.; Wang, Y.J.; Yan, Q.; et al. Long-term efficacy of a hepatitis E vaccine. *N. Engl. J. Med.* **2015**, *372*, 914–922. [CrossRef]

205. Joshi, R.M. Hepatitis E Virus: A Renewed Hope with Hecolin. *Clin. Microbiol. Open Access* **2015**, *04*. [CrossRef]

206. Wu, T.; Zhu, F.C.; Huang, S.J.; Zhang, X.F.; Wang, Z.Z.; Zhang, J.; Xia, N.S. Safety of the hepatitis E vaccine for pregnant women: A preliminary analysis. *Hepatology* **2012**, *55*, 2038. [CrossRef]

207. Li, M.; Li, S.; He, Q.; Liang, Z.; Wang, L.; Wang, Q.; Wang, L. Hepatitis E-related adverse pregnancy outcomes and their prevention by hepatitis E vaccine in a rabbit model. *Emerg. Microbes Infect.* **2019**, *8*, 1066–1075. [CrossRef] [PubMed]

208. Zaman, K.; Dudman, S.; Stene-Johansen, K.; Qadri, F.; Yunus, M.; Sandbu, S.; Gurley, E.S.; Overbo, J.; Julin, C.H.; Dembinski, J.L.; et al. HEV study protocol: Design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh. *BMJ Open* **2020**, *10*, e033702. [CrossRef] [PubMed]

209. Hepatitis E vaccine: Why wait? *Lancet* **2010**, *376*, 845. [CrossRef]